1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm
3 Cash-Producing Stocks with Exciting Potential
2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
SAN DIEGO , April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into...
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
SAN DIEGO , March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer...
FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression ‑free survival and overall survival versus standard of care regimens
SAN DIEGO , Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present...
2 Reasons to Like HALO (and 1 Not So Much)